New morpholine derivatives as 5HT2C receptor agonists for the treatment of obesity
申请人:Bentley Mark Jonathan
公开号:US20060178510A1
公开(公告)日:2006-08-10
The present invention refers to chemical compounds of formula (I)
as well as pharmaceutically acceptable salts and esters thereof, wherein R
1
to R
5
have the significance given in claim
1.
These compounds can be used for the preparation of medicaments.
Morpholine derivatives as 5HT2C receptor agonists for the treatment of obesity
申请人:Hoffman-La Roche Inc.
公开号:US07323466B2
公开(公告)日:2008-01-29
The present invention refers to chemical compounds of formula (I)
as well as pharmaceutically acceptable salts and esters thereof, wherein R1 to R5 have the significance given in claim 1. These compounds can be used for the preparation of medicaments.
[EN] MORPHOLINES AS 5HT2C AGONISTS<br/>[FR] MORPHOLINES EN TANT QU'AGONISTES DE 5HT2C
申请人:HOFFMANN LA ROCHE
公开号:WO2006077025A2
公开(公告)日:2006-07-27
[EN] The present invention refers to chemical compounds of formula (I) as well as pharmaceutically acceptable salts and esters thereof, wherein R1 to R5 have the significance given in claim 1. These compounds can be used for the preparation of medicaments. [FR] Composés chimiques de formule (I) et sels et esters acceptables sur le plan pharmaceutique desdits composés. Dans ladite formule, R1 à R5 possèdent la signification figurant dans la revendication 1. Ces composés peuvent être utilisés pour la préparation de médicaments.